Abstract
The article focuses on the benefits and drawbacks of precision medicine. It comments on the cystic fibrosis drug ivacaftor which can treat around five percent of cystic fibrosis patients and was fast-tracked by the U.S. Food and Drug Administration in 2010, and mentions the drug costs 300,000 dollars a year per patient and could be treated equally using the antibiotic azithromycin, aerosolized saline, and high-dose ibuprofen. It examines the use of genetics in determining metabolism of warfarin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
